

Tufts CSDD 2020 Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation

Monday, February 3, 2020

Moderator:	Richard I. Shader, MD
8:00-8:30 am	<i>Open Registration, Continental Breakfast</i>
8:30-8:45 am	Welcome, Orientation, Course Objectives & Introduction Kenneth Kaitin
8:45-9:45 am	The Basics of the Drug Development Process and its Phases Richard Shader
9:45-10:00 am	<i>Refreshment Break</i>
10:00-11:00 am	Translational Medicine – Discovery to Development Chandrasekhar Natarajan
11:00-12:00 pm	Principles of Clinical Pharmacology Jerry Collins
12:00-1:00 pm	<i>Lunch Break</i>
Moderator:	Kenneth I Kaitin, PhD
1:00-2:00 pm	Clinical Pharmacologic Evaluation of Intrinsic and Extrinsic Factor Effects in Global Drug Development Karthik Venkatakrisnan
2:00-3:00 pm	Biosimilars: Challenges and Opportunities Alison Taunton-Rigby
3:00-4:00 pm	Drug Development Regulation Part 1: USA Alberto Grignolo
4:00-4:15 pm	<i>Refreshment Break</i>
4:15-5:15 pm	Drug Development Regulation Pt. 2: Brief Overview of EU, Japan, China and Emerging Markets Alberto Grignolo
5:15-6:00 pm	The Current Environment for Drug Development: Strategies for Boosting R&D Efficiency and Productivity Kenneth Kaitin
6:00-8:00 pm	<i>Networking Reception</i>

Tuesday, February 4, 2020

Moderator:	Richard I. Shader, MD
8:00-8:30 am	<i>Continental Breakfast</i>
8:30-9:15 am	The Basics of Clinical Trial Design Richard Shader
9:15-10:00 am	Institutional Review Boards: An Ethical and Regulatory Overview Susan Kornetsky
10:00-10:15 am	<i>Refreshment Break</i>
10:15-11:15 am	The Role of Chance in Randomized Controlled Trials: Lecture Janet Forrester
11:15-12:00 pm	Evaluating the Role of Chance in Clinical Trials: Workshop Janet Forrester
12:00-1:00 pm	<i>Lunch with Mock Drug Groups</i>
Moderator:	Richard I. Shader, MD
1:00-2:00 pm	The Next Wave of Adaptive Trials: Broad Implementation & Efficient Clinical Development Jerald Schindler
2:00-2:15 pm	Instant Experience in Clinical Trials Richard Shader
2:15-3:00 pm	Pre-Mock Drug Group Discussion Helen Boucher
3:00-5:30 pm	Mock Drug Groups: Session I Richard Shader, Helen Boucher & Paul Beninger

Wednesday, February 5, 2020

Moderator:	Richard I. Shader, MD
7:30-8:00 am	<i>Continental Breakfast</i>
8:00-10:00 am	Mock Drug Groups: Session II Richard Shader, Helen Boucher & Paul Beninger
10:00-10:15 am	<i>Refreshment Break</i>
10:15-11:15 am	Understanding the Medical Affairs Function Pol Vandembroucke
11:15-12:15 pm	Bio/Pharm Investing 101 Les Funtleyder
12:15-1:15 pm	<i>Lunch Break</i>
Moderator:	Kenneth I Kaitin, PhD
1:15-3:00 pm	Understanding the FDA: An Open Conversation and Q&A Ellis Unger
3:00-4:00 pm	Pharmaceutical Marketing & the New World Order of Advertising, Social Media and Regulation Laura Housman
4:00-5:45 pm	Mock Drug Groups: Presentations Richard Shader & Paul Beninger
5:45-7:30 pm	<i>Mid-Week Networking Reception: Take an Opportunity to Meet Someone New!</i>

Thursday, February 6, 2020

Moderator:	Kenneth I Kaitin, PhD
8:30-9:00 am	<i>Continental Breakfast</i>
9:00-10:00 am	Optimizing Protocol Design to Improve Study Conduct Performance Kenneth Getz
10:00-11:00 am	Basics of CMC/Quality in Drug Development Robert Morgan
11:00-11:15 am	<i>Refreshment Break</i>
11:15-12:15 pm	Regulatory Science: An Integrated Approach of Evidence Generation for Regulatory Approval & Optimal Label Iman Barilero
12:15-1:15 pm	<i>Lunch Break</i>
Moderator:	Richard I. Shader, MD
1:15-2:15 pm	Pharmacovigilance, Post-Market Surveillance, and Risk Management Paul Beninger
2:15-2:45 pm	Drug Safety Breakout Group Discussion Paul Beninger
2:45-4:15 pm	Breakout Group Activity: Drug Safety – Stakeholder Perspectives Paul Beninger, Kenneth Kaitin & Richard Shader
4:15-5:30 pm	<i>“MEET THE PRESS: Should This Life-Saving Medicine with Safety Issues Remain on the Market?”</i> Paul Beninger & Kenneth Kaitin
5:30-5:45 pm	Drug Safety Breakout Group Activity Wrap-Up Paul Beninger

Friday, February 7, 2020

Moderator:	Kenneth I Kaitin, PhD
8:15-8:45 am	<i>Continental Breakfast</i>
8:45-9:45 am	Measuring the Value of Prescription Drugs Peter Neumann
9:45-10:45 am	Patient Centricity’s Impact on Drug Development Kenneth Getz
10:45-11:45 am	How to Select and Work with CRO’s Laurie Halloran
11:45-12:00 pm	Course Wrap-Up Kenneth I Kaitin